Proximal subungual onychomycosis caused by Fusarium falciforme successfully cured with posaconazole

British Journal of Dermatology

Volumn 173, Issue 1, 2015, Pages 253-255

  Al Hatmi, A M S ^a,b,c   Bonifaz, A ^d   Calderon L ^d   Curfs Breuker, I ^e   Meis, J F ^e,f   Van Diepeningen, A D ^a   De Hoog, G S ^{a,b,g,h,i,j,k}  

^a ROYAL NETHERLANDS ACADEMY OF ARTS AND SCIENCES   (Netherlands)

^b UNIVERSITY OF AMSTERDAM   (Netherlands)

^c MINISTRY OF HEALTH   (Oman)

^d HOSPITAL GENERAL DE MÉXICO   (Mexico)

^e CANISIUS WILHELMINA HOSPITAL   (Netherlands)

^f RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^g PEKING UNIVERSITY HEALTH SCIENCE CENTER   (China)

^h SUN YAT SEN UNIVERSITY   (China)

ⁱ SECOND MILITARY MEDICAL UNIVERSITY   (China)

^j FEDERAL UNIVERSITY OF PARANÁ   (Brazil)

^k KING ABDULAZIZ UNIVERSITY   (Saudi Arabia)

more..

Author keywords

[No Author keywords available]

Indexed keywords

AMPHOTERICIN B; ATAZANAVIR; ELONGATION FACTOR 1ALPHA; INTERNAL TRANSCRIBED SPACER; ITRACONAZOLE; POSACONAZOLE; RIBOSOME RNA; RNA POLYMERASE; TERBINAFINE; VORICONAZOLE; ANTIFUNGAL AGENT; TRIAZOLE DERIVATIVE;

ADULT; AIDS PATIENT; ANTIFUNGAL SUSCEPTIBILITY; CASE REPORT; DRUG SUBSTITUTION; DRUG WITHDRAWAL; DYSPEPSIA; FUNGAL COLONIZATION; FUSARIOSIS; FUSARIUM; FUSARIUM FALCIFORME; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LETTER; MALE; MIDDLE AGED; MINIMUM INHIBITORY CONCENTRATION; NUCLEOTIDE SEQUENCE; OPERON; PARONYCHIA; PRIORITY JOURNAL; PROXIMAL SUBUNGUAL ONYCHOMYCOSIS; TOENAIL ONYCHOMYCOSIS; FOOT DERMATOSES; MOLECULAR GENETICS; ONYCHOMYCOSIS;

ANTIFUNGAL AGENTS; FOOT DERMATOSES; FUSARIOSIS; FUSARIUM; HUMANS; MALE; MIDDLE AGED; MOLECULAR SEQUENCE DATA; ONYCHOMYCOSIS; TRIAZOLES;

EID: 84948711940     PISSN: 00070963     EISSN: 13652133     Source Type: Journal    
DOI: 10.1111/bjd.13589     Document Type: Letter

References (15)

1. Baran R, McLoone N, Hay RJ, et al,. Could proximal white subungual onychomycosis be a complication of systemic spread? The lessons to be learned from Maladie Dermatophytique and other deep infections Br J Dermatol 2005; 153: 1023-5.
2. Hwang S, Suh M, Ha G, et al,. Onychomycosis due to nondermatophytic molds. Ann Dermatol 2012; 24: 175-80.
3. Nucci M, Anaissie E,. Fusarium infections in immunocompromised patients. Clin Microbiol Rev 2007; 20: 695-704.
4. ® registry. Mycoses 2014; 57: 652-8.
5. O'Donnell K, Sutton DA, Fothergill A, et al,. Molecular phylogenetic diversity, multilocus haplotype nomenclature, and in vitro antifungal resistance within the Fusarium solani species complex. J Clin Microbiol 2008; 46: 2477-90.
6. Summerbell R, Schroers H,. Analysis of phylogenetic relationship of Cylindrocarpon lichenicola and Acremonium falciforme to the Fusarium solani species complex and a review of similarities in the spectrum of opportunistic infections caused by these fungi. J Clin Microbiol 2002; 40: 2866-75.
7. Gupta A, Drummond-Main C, Cooper A, et al,. Systematic review of nondermatophyte mold onychomycosis: diagnosis, clinical types, epidemiology and treatment. J Am Acad Dermatol 2012; 66: 494-502.
8. Johnson R,. HIV Disease: mucocutaneous fungal infections in HIV disease. Dermatol Clin 2000; 18: 411-22.
9. Hay R, Baran R,. Onychomycosis: a proposed revision of the clinical classification. J Am Acad Dermatol 2011; 65: 1219-27.
10. Kuruvilla T, Dias M,. Fusarium solani: a causative agent of skin and nail infections. Indian J Dermatol 2012; 57: 308-9.
11. Bonifaz A, Paredes V, Fierro L, et al,. Paronychia. Skinmed 2013; 11: 14-16.
12. Nucci M, Varon A, Garnica M, et al,. Increased incidence of invasive fusariosis with cutaneous portal of entry, Brazil. Emerg Infect Dis 2013; 19: 1567-72.
13. Elewski B, Pollak R, Ashton S, et al,. A randomized, placebo- and active-controlled, parallel-group, multicentre, investigator-blinded study of four treatment regimens of posaconazole in adults with toenail onychomycosis. Br J Dermatol 2012; 166: 389-98.
14. Krishna G, Ma L, Martinho M, et al,. Determination of posaconazole levels in toenails of adults with onychomycosis following oral treatment with four regimens of posaconazole for 12 or 24 weeks. Antimicrob Agents Chemother 2011; 55: 4424-6.
15. Al-Hatmi AM, van Diepeningen AD, Curfs-Breuker I, et al,. Specific antifungal susceptibility profiles of opportunists in the Fusarium fujikuroi complex. J Antimicrob Chemother 2015; 70: 1068-71.